Trial reportJournal of Crohn's & colitis2026
Hyperbaric oxygen therapy alters bowel perfusion and improves outcomes in patients with treatment-refractory ulcerative colitis: a prospective pilot trial.
Trial report in Journal of Crohn's & colitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundHyperbaric oxygen therapy (HBOT) delivers 100% oxygen in a pressurized chamber and enhances tissue oxygenation and neovascularization. While effective in radiation proctitis, acute severe ulcerative colitis, and perianal fistulizing Crohn's disease, its role in refractory ulcerative colitis (UC) remains underexplored.
methodsPARADOX was a prospective, open-label, phase 2a pilot trial in biologic-experienced patients with moderate-to-severe refractory UC (total Mayo > 5, Mayo endoscopic subscore (MES) ≥ 2, failure of ≥ 2 advanced therapies). Patients received 10 or 20 daily HBOT sessions (2.4 atmospheres absolute, 120 minutes/day) while continuing stable background therapy. The primary endpoint was composite clinical and endoscopic response at week 12 (≥ 3-point and 30% Mayo score reduction, rectal bleeding score = 0, and ≥ 1-point decrease in MES). Secondary outcomes included symptomatic, biochemical, and transmural response by intestinal ultrasound (IUS), including perfusion metrics via contrast-enhanced ultrasound (CEUS).
resultsIn total, 16 patients (8 per group) were included in this pilot study. At week 12, composite response was achieved in 2/8 (10-session) and 4/8 (20-session) patients. Improvements in clinical, endoscopic, and IUS parameters were observed in both groups. Clinical responders showed increased CEUS perfusion at week 12 (peak enhancement Δ12.1 dB), while non-responders declined (Δ -5.4 dB). This pattern was consistent across wash-in/wash-out metrics, supporting a volume perfusion-based response. HBOT was well tolerated, with no serious adverse events or treatment discontinuations.
conclusionHBOT is a well-tolerated adjunctive therapy in refractory UC, which improved clinical outcomes and perfusion kinetics. These findings support further evaluation in a randomized, dose-optimized trial.Euclinicaltrials.eu, EU CT number 2024-515278-28-00.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.